About 235,945 results

Natural History and Development of Spondyloarthritis

Sep 28th, 2022 - The purpose of this protocol is to study the natural history of spondyloarthritis (SpA) in children and adults. Spondyloarthritis encompasses a spectrum of immune-mediated inflammatory diseases that exhibit overlapping features, but differ from other types of inflammatory arthritis in genetic predisposition, pathogenesis, and outcome. Ankylosing spondylitis (AS), the most common form of SpA, fr...

Fluconazole - fluconazole tablet-REMEDYREPACK INC.

Dec 30th, 2022 - Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, di...

Transcriptome Profiling and Autoimmunity-related Serological Markers Identify Tumour Protein P53 and Complement C3a Receptor 1 as Drug Targets in Neuropsychiatric Systemic Lupus Erythematosus
Julius Lindblom, Daniel Toro-Domínguez, Elena Carnero-Montoro et. al.

Nov 14th, 2022 - Background/Purpose: Involvement of the nervous system is a common but poorly understood manifestation of SLE, termed NPSLE. Although studies have reported varying prevalence estimates (Unterman et al. 2011), NPSLE affects at least 20% of patients with SLE within the first years of the disease course (Hanly et al. 2010). The management of NPSLE is poorly optimised and specific treatment is lacki...

Cycling versus Swapping Strategies in Psoriatic Arthritis: Results from the Rheumatic Diseases Portuguese Register
Francisca Guimarães, Maria Pontes-Ferreira, Catarina Soares et. al.

Nov 14th, 2022 - Background/Purpose: This study aimed to compare the effectiveness and safety of switching to a second tumour necrosis factor alfa inhibitor (TNFi) – “cycling group” – versus a drug with a different mode of action, secukinumab (SEK) or ustekinumab (UST) – “swapping group”, measured by retention rates during a 2-year period of follow-up, in Psoriatic Arthritis (PsA) patients with previous inadequ...

Cycling vs Swapping Strategies with TNFi and IL-17i in Psoriatic Arthritis: An Observational Retrospective Monocentric Study
Federica Lumetti, Alarico Ariani, Camilla Coccolini et. al.

Nov 14th, 2022 - Background/Purpose: The therapy of psoriatic arthritis (PsA) was amplified in the last years with the introduction of a large amount of new biologic molecules with different mechanisms of action (MoA). In clinical practice, the most frequently prescribed biologics are interleukin-17 inhibitors (IL17i) and tumor necrosis factor-alpha inhibitors (TNFαi). There is an increased interest in the defi...

Baseline Biomarkers Predict Better Responses to Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis
Oliver FitzGerald, Dafna Gladman, Philip J Mease et. al.

Nov 14th, 2022 - Background/Purpose: Deucravacitinib (DEUC) is a novel, oral, selective TYK2 inhibitor with a unique allosteric mechanism of action that has demonstrated efficacy in patients with psoriasis1 and PsA.2 TYK2 mediates signaling of select immune cytokines, eg, IL-23, IL-12, and Type I IFN, whereas the related Janus kinases (JAK) 1/2/3 mediate signaling of a wider array of cytokines and mediators inv...

Safety of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor: As Assessed by Laboratory Parameters – Results from a Phase 2 Trial in Psoriatic Arthritis and 2 Phase 3 Trials in Psoriasis
Roy Fleischmann, Diamant Thaci, Melinda Gooderham et. al.

Nov 14th, 2022 - Background/Purpose: Deucravacitinib (DEUC) is a novel, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of action distinct from Janus kinase (JAK) 1/2/3 inhibitors. DEUC mediates signaling of key cytokines in PsA and psoriasis (PsO). DEUC was well tolerated and efficacious vs placebo (PBO) in a phase 2 trial in patients with PsA,1 and vs PBO or apremilast i...

mTORC2 Contributes to Murine Systemic Autoimmunity
Xian Zhou, Haiyu Qi, Meilu Li et. al.

Nov 14th, 2022 - Background/Purpose: The development of many systemic autoimmune diseases, including systemic lupus erythematosus, is associated with overactivation of the type I interferon (IFN) pathway, lymphopenia, and imbalance between follicular helper T (Tfh) cell and regulatory T cells (Treg). However, the cellular and molecular mechanisms underlying these immunological perturbations remain incompletely ...

Gut Microbe-derived Short-Chain Fatty Acids Regulate Arthritis and Myositis During Chikungunya Virus Infection
Fang R. Zhao, Emma Winkler, Chun-Jun Guo et. al.

Nov 14th, 2022 - Background/Purpose: The intestinal microbiota regulates musculoskeletal inflammation and antibiotic use increases risk for the development or relapse of inflammatory arthritis. However, the basis for this is not well understood. Even less is known about the effects of the commensal intestinal microbiota on tissue inflammation in the context of viral arthritis such as that resulting from chikung...

Does Ancestry Influence Primary Sjögren’s Syndrome Phenotype or Severity?
Maxime Beydon, Marie Dulin, Raphaèle Seror et. al.

Nov 14th, 2022 - Background/Purpose: It is well established that in systemic lupus erythematous (SLE), disease burden is higher in patients from African ancestry (AA) than in Caucasian patients. Although primary Sjögren’s syndrome (pSS) and SLE vary by their clinical presentation, they share common pathogenic mechanisms. Our objectives were to compare demographic and biological parameters as well as disease act...

Hazard Index Equations Using Data Collected at Baseline and After One Year Treatment Allow Early Prediction of Poor Outcome in an Incident Lupus Nephritis Population: Data from the Louvain Lupus Ne...
Farah Tamirou and Frédéric A. Houssiau, Cliniques Universitaires Saint-Luc, Brussels et. al.

Nov 14th, 2022 - Background/Purpose: While long-term follow-up (FU) is needed to unmask poor outcome in lupus nephritis (LN), most clinical trials evaluate outcome measures at short-term. Early endpoints predictive of long-term outcome in LN are therefore most welcome to compare efficacy of pharmacological interventions. A multicentric study, using a large database of prospectively followed LN patients, succeed...

Early Histopathological Changes of the Salivary Glands Associated with the Development of Primary Sjögren’s Syndrome
Xiaomei Shan, Clara Reichardt, Jeeshan Singh et. al.

Nov 14th, 2022 - Background/Purpose: Primary Sjögren’s syndrome (PSS) is a chronic inflammatory disease affecting exocrine glands including salivary and lacrimal glands that leads to dry eyes and mouth along with various systemic manifestations. While in established disease, systemic adaptive immune system activation is a key process in PSS and autoantibodies against nuclear proteins (Ro, La) are formed, the in...

In Vitro Response to Disease Modifying Antirheumatic Drugs Link Molecular Drug Target with Synovial Transcriptional Signature
Mads Brüner, Ulvi Ahmadov, Morten Aagaard Nielsen et. al.

Nov 14th, 2022 - Background/Purpose: Immune-mediated inflammatory arthritis (IMIA) is a group of diseases characterized by chronic synovitis including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondyloarthritis (SpA). Some disease modifying antirheumatic drugs (DMARDs) have demonstrated efficacy in several of these diseases (e.g. TNFα inhibitors) while others have not (e.g. IL-17A inhibitors in ...

AUR200: An Improved BAFF/APRIL Inhibitor with Increased Potency and Safety for the Treatment of B Cell-Mediated Diseases
Shawn Morales, Jennifer Cross and Robert Huizinga, Aurinia Pharmaceuticals et. al.

Nov 14th, 2022 - Background/Purpose: AUR200 targets both B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), which are key mediators in the pathogenesis of B cell-mediated autoimmune diseases. Dual blockade of BAFF and APRIL is proposed to be more effective than targeting either molecule alone. AUR200 is a potent recombinant IgG4 Fc fusion protein containing a modified B cell maturation...

Interferon Alpha Promotes Ultraviolet Light-Mediated Keratinocyte Apoptosis in a Caspase-8 Dependent Manner via Upregulation of Interferon Regulatory Factor 1
Shannon Estadt, Mehrnaz Gharaee-Kermani, Bin Xu et. al.

Nov 14th, 2022 - Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by enhanced sensitivity to ultraviolet radiation (UVR). UVR can trigger cutaneous and systemic disease flares, yet mechanisms driving these responses are not yet fully characterized. Type I interferons (IFNs) are overexpressed in non-lesional SLE skin compared to healthy control skin and promote...

Dermatomyositis (DM) Macrophages Upregulate Genes Involved in the Remodeling of the Extracellular Matrix and Activate Keratinocytes in a Novel 3D Tissue Model of DM Skin Disease
Zoe Chafouleas, Angelique Cortez, James Whitley et. al.

Nov 14th, 2022 - Background/Purpose: With an incidence of 10 cases per million and lack of animal or ex vivo disease models, dermatomyositis (DM) remains a debilitating disease without a cure or the understanding of the pathogenic mechanisms. Recent studies showed that monocytes and macrophages reside in DM skin and demonstrate diverse phenotypes. While keratinocytes in DM skin have an inflammatory gene signatu...

The TLR7/8 Inhibitor Enpatoran Reverses Established Kidney Disease in the Interferon-Alpha-Accelerated NZB/W Mouse Model of Lupus
Julia Bruttger, Andrew Bender, Sonja Reissig et. al.

Nov 14th, 2022 - Background/Purpose: Activation of toll-like receptor 7 and 8 (TLR7/8) signaling by single-stranded RNA results in immune cell stimulation and inflammatory cytokine production, a normal circumstance in a protective antiviral host response. In autoimmune conditions such as lupus, aberrant activation of TLR7/8 can be pathogenic and contribute to disease progression. The primary cell types stimulat...

Age-Dependent Expansion and Activation of Disease-Associated Microglia in Neuropsychiatric Symptoms of Systemic Lupus Erythematosus
Hadijat Makinde, Caroline Shah, Miranda Gurra et. al.

Nov 14th, 2022 - Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease that affects multipe end organs, including the brain. Despite a prevalence of over 50% in SLE patients depending on the attribution model, neuropsychiatric symptoms of SLE (NPSLE) are among the least understood complications. Notwithstanding the paucity of data examining underlying mechanisms, accumulating ev...

Differentiation of Injury-associated Macrophages in Lupus Kidneys Is Conserved in Humans and Lupus Mouse Models
Paul Hoover, David Lieb, Stephen Li et. al.

Nov 14th, 2022 - Background/Purpose: Infiltrating monocytes acquire functions that support kidney remodeling in response to tissue damage in lupus nephritis. This process of monocyte differentiation has been difficult to study due to the inability to characterize immune cells from small human kidney biopsies or to accurately use mouse models to investigate mechanisms relevant to human disease. We previously rep...

TRIM21 as a Regulator of UVB-Driven IFN Responses in Lupus
Richard Moore, Gantsetseg Tumurkhuu, Daniel Wallace and Caroline Jefferies et. al.

Nov 14th, 2022 - Background/Purpose: Patients with systemic lupus erythematosus (SLE) experience photosensitivity where exposure to ultraviolet light B (UVB) drives lupus flares and systemic symptoms. Although the mechanisms linking UVB exposure to these effects are unclear, type I IFNs are known to play a role. TRIM21, an autoantigen in SLE, functions as a negative regulator on the pathways driving IFN express...